Market Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...

For a limited time, he's revealing his latest forecast here.

Kirk Allen Coleman net worth and biography

Kirk Coleman Biography and Net Worth

CFO of TFF Pharmaceuticals

Mr. Coleman has served as our Chief Financial Officer since January 2018. Since 2012, Mr. Coleman has also served as an executive officer of Steelhead Capital Management, LLC and Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies.

From 1998 to 2008, Mr. Coleman was Treasurer for EFO Holdings, LP, a family office. Mr. Coleman has over 20 years of financial and accounting experience. Mr. Coleman received a BBA in Accounting from Texas Christian University in 1995.

What is Kirk Allen Coleman's net worth?: The estimated net worth of Kirk Allen Coleman is at least $1,235.19 as of March 10th, 2023. Mr. Coleman owns 627 shares of TFF Pharmaceuticals stock worth more than $1,235 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Coleman may own. Additionally, Mr. Coleman receives an annual salary of $409,940.00 as CFO at TFF Pharmaceuticals. Learn More about Kirk Allen Coleman's net worth.
How old is Kirk Allen Coleman?: Mr. Coleman is currently 50 years old. There are 2 older executives and no younger executives at TFF Pharmaceuticals. The oldest executive at TFF Pharmaceuticals is Dr. Harlan F. Weisman, President, CEO & Director, who is 72 years old. Learn More on Kirk Allen Coleman's age.
What is Kirk Allen Coleman's salary?: As the CFO of TFF Pharmaceuticals, Inc., Mr. Coleman earns $409,940.00 per year. There are 2 executives that earn more than Mr. Coleman. The highest earning executive at TFF Pharmaceuticals is Dr. Harlan F. Weisman, President, CEO & Director, who commands a salary of $742,500.00 per year. Learn More on Kirk Allen Coleman's salary.
How do I contact Kirk Allen Coleman?: The corporate mailing address for Mr. Coleman and other TFF Pharmaceuticals executives is 2600 Via Fortuna Suite 360, Austin TX, 78746. TFF Pharmaceuticals can also be reached via phone at 817-438-6168 and via email at [email protected]. Learn More on Kirk Allen Coleman's contact information.
Has Kirk Allen Coleman been buying or selling shares of TFF Pharmaceuticals?: Kirk Allen Coleman has not been actively trading shares of TFF Pharmaceuticals during the last quarter. Most recently, on Friday, March 10th, Kirk Allen Coleman bought 480 shares of TFF Pharmaceuticals stock. The stock was acquired at an average cost of $19.75 per share, with a total value of $9,480.00. Following the completion of the transaction, the chief financial officer now directly owns 627 shares of the company's stock, valued at $12,383.25. Learn More on Kirk Allen Coleman's trading history.
Who are TFF Pharmaceuticals' active insiders?: TFF Pharmaceuticals' insider roster includes Kirk Coleman (CFO), Malcolm Fairbairn (Director), and Glenn Mattes (CEO). Learn More on TFF Pharmaceuticals' active insiders.

Kirk Allen Coleman Insider Trading History at TFF Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2023	Buy	480	$19.75	$9,480.00	627
5/16/2022	Buy	50	$110.00	$5,500.00	130
9/16/2021	Buy	40	$182.50	$7,300.00
3/15/2021	Sell	200	$426.25	$85,250.00	240
1/15/2021	Sell	200	$437.50	$87,500.00	240
12/23/2020	Sell	400	$381.00	$152,400.00	440
11/10/2020	Sell	600	$378.00	$226,800.00	640
10/25/2019	Buy	40	$125.50	$5,020.00

Kirk Allen Coleman Buying and Selling Activity at TFF Pharmaceuticals

TFF Pharmaceuticals Company Overview

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Today's Range

Now: $1.97

$1.89

$2.46

50 Day Range

MA: $2.10

$1.79

$2.51

2 Week Range

Now: $1.97

$1.35

$11.00

Volume

150,370 shs

Average Volume

111,757 shs

Market Capitalization

$6.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Market "Famine" Coming

From Opportunistic Trader | Ad